Published in Vaccine Weekly, May 3rd, 2006
CytRx expects to report final data from this Phase IIa trial in the third quarter of this year, followed by initiation of a Phase IIb efficacy trial, subject to approval from the U.S. Food and Drug Administration (FDA).
"We are exceptionally pleased to complete enrollment so rapidly, which we believe indicates favorable interest from the ALS community for arimoclomol as a potential treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly